ELEGEN CORP.

Belmont, CA · Biotech · Private

Benchtop microfluidic instrument for rapid, low-cost DNA synthesis

Claim this profile

Follows are private to you and power your alerts

Updated · elegenbio.com

Sector
Biotech
Headquarters
Belmont, CA
Latest Form D
$33M, May 2024
Total capital
$37M
Federal grants
$4M
3 awards · 2020–2021
Rank in peer group#2 of 17
Private capital raised
$33M
1 Form D · last May 2024
29 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
0
6 pending

Capital timeline

20202021202220232024FEDERAL ↑EQUITY ↓Cumulative $37M$1.2M$2M$790K1st Form D$33M
20202021202220232024FEDERAL ↑EQUITY ↓Cumulative $37M$1.2M$2M$790K1st Form D$33M

Latest events

  • Private capital raisedForm D · SEC · 1st filing$33M
  • Federal grantHealth and Human S · Phase II · Novel microfluidic platform for versatile, fast, low-cost DNA synthesis and assembly$790K
  • Federal grantHealth and Human S · Phase II · Novel microfluidic platform for versatile, fast, low-cost DNA synthesis and assembly$2M
  • Federal grantHealth and Human S · Phase II · Novel microfluidic platform for versatile, fast, low-cost DNA synthesis and assembly$1.2M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Federal first

44months

from ELEGEN CORP.’s first federal award to its first private round.

First federal award · Sep 2020
Health and Human S · $1.2M
First Form D · May 2024
$33M · 1st Form D
Awards before first raise
3 awards

An association in public records, not a cause or a prediction.

Standing among 17 peers

Line = median

Biotech · Device

  • Federal grants#2 · top 12%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants
  • Matthew HillResearcherExecutive Officer, DirectorLinked by $4M in grants as PI
  • Cain McClaryDirectorNamed in SEC Form D filings
  • Jonathan SheenaDirectorNamed in SEC Form D filings
  • Peter ZhouDirectorNamed in SEC Form D filings

What it has protected

USPTO · 0 granted of 6
  • PendingBead-sorting Systems And Methods Of Use ThereofUSPTOApplication 63240849
  • PendingBead-sorting Systems And Methods Of Use ThereofUSPTOApplication 63240836
  • PendingMethods And Compositions For Cell-free CloningUSPTOApplication 63174192
Show all 6 patent records
  • Bead-sorting Systems And Methods Of Use ThereofApplication 63240849Pending
  • Bead-sorting Systems And Methods Of Use ThereofApplication 63240836Pending
  • Methods And Compositions For Cell-free CloningApplication 63174192Pending
  • Bead-sorting Systems And Methods Of Use Thereof Using Pressure SourcesApplication 63240844Pending
  • Multi-way Bead-sorting Devices, Systems, And Methods Of Use Thereof Using Pressure SourcesApplication PCTUS2022075957Pending
  • Methods And Compositions For Cell-free CloningApplication PCTUS2022071707Pending

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .